Quality over quantity: biopsy-anchored CT radiogenomics models outperform all-lesion training in a multi-tumour cohort despite a smaller sample size
Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: Radiogenomics aims to non-invasively predict tumour genotypes from imaging, but most studies assume molecular homogeneity by assigning a single biopsy-derived label to all lesions within a patient. This approach risks substantial label noise given well-documented interlesional heterogeneity. We investigated whether anchoring training to biopsy-confirmed lesions improves radiogenomic model performance and generalisability. MATERIALS AND METHODS: We retrospectively analysed 1646 patients (11473 segmented lesions) with contrast-enhanced CT and EGFR mutation status from next-generation sequencing at the Netherlands Cancer Institute, alongside an external NSCLC radiogenomics cohort (n = 158). All visible lesions were segmented, and the exact biopsy site was matched to its segmentation. Radiomic features were extracted, and machine learning models were trained with three lesion selection strategies: all lesions, non-biopsied lesions only, and biopsy-confirmed lesions only. To disentangle label quality from sample size, we created size-matched variants (one lesion per patient) for all-lesion and non-biopsied strategies. RESULTS: All models achieved significant discrimination of EGFR status on internal validation (AUC = 0.62-0.68). However, performance of the all-lesion and non-biopsied models declined on external validation (AUC = 0.55-0.63), while the biopsy-anchored model maintained stable performance (AUC = 0.62), despite having only 1/10th of the training sample size. When training sets were size-matched, the biopsy-anchored approach significantly outperformed a model trained on all available lesions on external validation (p = 0.037). CONCLUSIONS: Radiogenomic models trained on biopsy-confirmed lesions outperform conventional all-lesion strategies in external validation, despite using an order of magnitude fewer samples. Prioritising lesion-level label fidelity can mitigate heterogeneity-driven noise, enhancing robustness and clinical translation of imaging-based genomic prediction. KEY POINTS: Question Does assigning biopsy-derived molecular labels to all lesions introduce heterogeneity-driven label noise that reduces the generalisability of radiogenomic models? Findings Models trained exclusively on biopsy-confirmed lesions demonstrated superior external generalisability compared with all-lesion approaches, despite being trained on substantially fewer samples. Clinical relevance Biopsy-anchored radiogenomics improves the reliability of non-invasive mutation prediction by accounting for tumour heterogeneity, potentially supporting clinical decision-making when tissue sampling is limited or molecular results are discordant across lesions.
Source: European Radiology
Authors: Diana Ivonne Rodríguez Sánchez, Julian Middelkoop, Thera Vanneste, Olga Maxouri, Stephan Ursprung, Sajjad Rostami, Nino Bogveradze, Kalina Chupetlovska, Francesca Castagnoli, Federica Landolfi, Eun Kyoung Hong, Andrea Delli Pizzi, Nicolo Gennaro, Warissara Jutidamrongphan, Liliana Petrychenko, Petur Snaebjornsson, Zuhir Bodalal, Regina Beets-Tan
Institutions: The Netherlands Cancer Institute, Maastricht University, Universitätsklinikum Tübingen, University of Tübingen, Institute of Cancer Research, Royal Marsden Hospital, Azienda Ospedaliera Sant'Andrea, Sapienza University of Rome, Stanford University, University of Chieti-Pescara, Northwestern University, Ente Ospedaliero Cantonale, Istituto Imaging della Svizzera Italiana, University of Bern, University Hospital of Bern, University of Iceland, University of Southern Denmark
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,890
OpenAlex ID: W7161445842
